| human | Q5 |
| P496 | ORCID iD | 0000-0002-1734-5772 |
| P69 | educated at | University of Oxford | Q34433 |
| University of Cambridge | Q35794 | ||
| Institute of Cancer Research | Q6039999 | ||
| P108 | employer | Queen Mary University of London | Q195668 |
| Public Health England | Q7257402 | ||
| Barts Health NHS Trust | Q4865798 | ||
| Institute of Cancer Research | Q6039999 | ||
| Guy's and St Thomas' NHS Foundation Trust | Q16993504 | ||
| Genomics England | Q18159990 | ||
| General Organization For Teaching Hospitals and Institutes | Q30265188 | ||
| William Harvey Research Institute | Q30273876 | ||
| Royal Marsden Hospital | Q50575536 | ||
| P735 | given name | Clare | Q16275208 |
| Clare | Q16275208 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q57920219 | 35th Annual Meeting of the European Association for the Study of Diabetes |
| Q56883844 | 35th Annual Meeting of the European Association for the Study of Diabetes : Brussels, Belgium, 28 September-2 October 1999 |
| Q28943448 | A genome-wide association study identifies susceptibility loci for Wilms tumor |
| Q29417036 | A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age. |
| Q33855633 | A genome-wide association study of testicular germ cell tumor |
| Q36435849 | A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. |
| Q92711687 | A network analysis to identify mediators of germline-driven differences in breast cancer prognosis |
| Q57319454 | Abstract 2986: Meta-analysis of whole exome sequencing data reveals the mutational spectrum of testicular germ cell tumors |
| Q57269984 | Abstract 842: Two new loci and gene sets related to sex determination and cancer progression are associated with susceptibility to testicular germ cell tumor |
| Q97070156 | Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers |
| Q30253080 | Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study |
| Q37151879 | Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer |
| Q35532898 | Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium |
| Q35832295 | BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years |
| Q34327945 | Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 |
| Q57305977 | Breast-Cancer Risk in Families With Mutations in PALB2 |
| Q34148873 | Breast-cancer risk in families with mutations in PALB2 |
| Q90315966 | Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network |
| Q49498007 | Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 Genomes Project. |
| Q95604482 | Collateral damage: the impact on cancer outcomes of the COVID-19 pandemic |
| Q95637487 | Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic |
| Q102151566 | Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations |
| Q38322815 | Common variants identified in genome-wide association studies of testicular germ cell tumour: an update, biological insights and clinical application |
| Q31082788 | Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q90262064 | Concern regarding classification of germline TP53 variants as likely pathogenic |
| Q34181322 | Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer |
| Q52584688 | Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group. |
| Q57278898 | Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC) |
| Q49486272 | Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. |
| Q48526678 | Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. |
| Q38687607 | Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry |
| Q28388475 | Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations |
| Q52603806 | Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. |
| Q34160764 | DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome |
| Q35124732 | Development of cancer genetic services in the UK: A national consultation |
| Q97678505 | Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study |
| Q102140826 | Estimated impact of the COVID-19 pandemic on cancer services and excess 1-year mortality in people with cancer and multimorbidity: near real-time data on cancer care, cancer deaths and a population-based cohort study |
| Q97552706 | Etiologic Index - A Case-Only Measure of BRCA1/2-Associated Cancer Risk |
| Q34017597 | Gene-gene interactions in breast cancer susceptibility |
| Q37187786 | Genetic predisposition to breast cancer: past, present, and future |
| Q91362827 | Genetic predisposition to mosaic Y chromosome loss in blood |
| Q61229415 | Genetic predisposition to mosaic Y chromosome loss in blood is associated with genomic instability in other tissues and susceptibility to non-haematological cancers |
| Q36842233 | Genome-wide association analysis identifies three new breast cancer susceptibility loci |
| Q35996692 | Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer |
| Q24622610 | Genome-wide association studies identify four ER negative-specific breast cancer risk loci |
| Q37882000 | Genome-wide association studies provide new insights into the genetic basis of testicular germ-cell tumour |
| Q34114293 | Genome-wide association study identifies five new breast cancer susceptibility loci |
| Q24628710 | Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls |
| Q64040390 | Genome-wide association study of germline variants and breast cancer-specific mortality |
| Q40447381 | Genomic evolution and chemoresistance in germ-cell tumours. |
| Q94521117 | Genomic landscape of platinum resistant and sensitive testicular cancers |
| Q57266552 | Germline RAD51C mutations confer susceptibility to ovarian cancer |
| Q28245028 | Germline mutations in RAD51D confer susceptibility to ovarian cancer |
| Q35102646 | Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk |
| Q39182862 | Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor |
| Q36839486 | Identification of four new susceptibility loci for testicular germ cell tumour |
| Q36859142 | Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer |
| Q36086247 | Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus |
| Q36922317 | Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14 |
| Q40310422 | Implications of polygenic risk for personalised colorectal cancer screening |
| Q62583667 | Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology |
| Q50056532 | Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene. |
| Q29416989 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk |
| Q36043843 | Mammographic breast density and breast cancer: evidence of a shared genetic basis |
| Q38626454 | Mendelian randomisation analysis provides no evidence for a relationship between adult height and testicular cancer risk |
| Q48102990 | Mendelian randomisation study of the relationship between vitamin D and risk of glioma |
| Q61445565 | Mendelian randomization provides support for obesity as a risk factor for meningioma |
| Q37046338 | Meta-analysis identifies four new loci associated with testicular germ cell tumor |
| Q40163628 | Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. |
| Q34497352 | MicroRNA related polymorphisms and breast cancer risk |
| Q28388006 | Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer |
| Q35221378 | Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25 |
| Q36785681 | Mutation and association analysis of GEN1 in breast cancer susceptibility |
| Q89927576 | Ovarian and breast cancer risks associated with pathogenic variants in RAD51C and RAD51D |
| Q34378988 | Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors |
| Q90171350 | Peridiagnostic and cascade cancer genetic testing |
| Q96577047 | Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q36750936 | Polygenic susceptibility to testicular cancer: implications for personalised health care |
| Q41905393 | Polygenic susceptibility to testicular cancer: implications for personalised health care |
| Q38611712 | Population genetic testing for cancer susceptibility: founder mutations to genomes |
| Q36583004 | Prediction of breast cancer risk based on profiling with common genetic variants |
| Q37194147 | Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer |
| Q98778292 | Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study |
| Q64277598 | Publisher Correction: Mendelian randomisation study of the relationship between vitamin D and risk of glioma |
| Q96816951 | Publisher Correction: Personalized early detection and prevention of breast cancer: ENVISION consensus statement |
| Q95601533 | Quantifying and mitigating the impact of the COVID-19 pandemic on outcomes in colorectal cancer |
| Q36039780 | Quantifying the heritability of testicular germ cell tumour using both population-based and genomic approaches |
| Q64004345 | Rapid reversal of clinical down-classification of a BRCA1 splicing variant avoiding psychological harm |
| Q37533259 | Rare disruptive mutations in ciliary function genes contribute to testicular cancer susceptibility |
| Q90386833 | Response to Letter to the Editor: "p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer" |
| Q37300024 | Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. |
| Q35987087 | Stratification of Wilms tumor by genetic and epigenetic analysis |
| Q90281955 | Structural Aberrations with Secondary Implications (SASIs): consensus recommendations for reporting of cancer susceptibility genes identified during analysis of Copy Number Variants (CNVs) |
| Q52332078 | Subphenotype meta-analysis of testicular cancer genome-wide association study data suggests a role for RBFOX family genes in cryptorchidism susceptibility. |
| Q34331070 | Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. |
| Q57090374 | The 100 000 Genomes Project: bringing whole genome sequencing to the NHS |
| Q30249650 | The genomic landscape of testicular germ cell tumours: from susceptibility to treatment |
| Q92952990 | Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report |
| Q38886775 | Two new loci and gene sets related to sex determination and cancer progression are associated with susceptibility to testicular germ cell tumor |
| Q52725335 | Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. |
| Q29417028 | Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer |
| Q98190418 | Weekly COVID-19 testing with household quarantine and contact tracing is feasible and would probably end the epidemic |
| Q35114280 | Whole-exome sequencing reveals the mutational spectrum of testicular germ cell tumours |
| Q88201782 | p.Val804Met, the Most Frequent Pathogenic Mutation in RET, Confers a Very Low Lifetime Risk of Medullary Thyroid Cancer |
Search more.